Drug Profile


Alternative Names: REGN-1033; SAR-391786

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Class Monoclonal antibodies
  • Mechanism of Action Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Muscular atrophy
  • Phase I Musculoskeletal disorders

Most Recent Events

  • 09 Jan 2017 Phase-I clinical trials in Musculoskeletal disorders (In volunteers, Combination therapy) in New Zealand (unspecified route) (NCT02943239)
  • 21 Oct 2016 Regeneron Pharmaceuticals plans a phase I trial in Healthy volunteers (Combination therapy) in New Zealand (NCT02943239)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Muscle-wasting(In volunteers) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top